Raising awareness on physician-patient communication in IPF: an Italian multicenter study exploring the pulmonologist’s perspective Physician-patient communication in IPF
Main Article Content
Keywords
Communication; Idiopathic pulmonary fibrosis; Questionnaire; Patient-centeredness; Role play; Semi-structured interviews; Training.
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) remains a debilitating, poor prognosis disease requiring a patient-centered approach.
Objectives: To explore the pulmonologist’s perspective on physician-patient communication.
Methods: A faculty of psychologists and pulmonologists organized a training course consisting of two workshops 12 months apart. Self-assessment questionnaires (pre- and post-course), role play (RP) simulations (during both workshops) and clinical consultation observations followed by semi-structured interviews (in the 12-month period) were employed to evaluate the pulmonologists’ knowledge of patient-centered medicine and communication/relational skills, their communication style and possible communication/relational difficulties.
Results: Twenty-three pulmonologists attended the first workshop, 14 the second one and 10 both. They were interested in patient-centered medicine and communication but felt the need for deeper knowledge and improved skills; during the first workshop, a more disease-oriented approach emerged. However, the training yielded some improvements, like more frequent patient agenda exploration. The patients’ poor knowledge of IPF was among the barriers hampering effective communication.
Conclusions: Despite the overall disease-prone approach to IPF patients, there was room for improvement through adequate training. In practice, adequate training may ameliorate communication and drive towards patient-centeredness. Raising awareness on these topics is crucial to ensure IPF patients optimal care. The pulmonologists’ needs may help planning interventions.
References
2. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017 May 13;389(10082):1941–52.
3. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010 Mar;35(3):496–504.
4. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2083–92.
5. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071–82.
6. Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.
7. Aiello M, Bertorelli G, Bocchino M, Chetta A, Fiore-Donati A, Fois A, et al. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017;44:7–15.
8. Lee AS, Mira-Avendano I, Ryu JH, Daniels CE. The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med. 2014 Jul;108(7):955–67.
9. Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM. The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review. Pharmacoeconomics. 2018;36(7):779–807.
10. Overgaard D, Kaldan G, Marsaa K, Nielsen TL, Shaker SB, Egerod I. The lived experience with idiopathic pulmonary fibrosis: a qualitative study. Eur Respir J. 2016;47(5):1472–80.
11. Yount SE, Beaumont JL, Chen S-Y, Kaiser K, Wortman K, Van Brunt DL, et al. Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. Lung. 2016 Apr;194(2):227–34.
12. Sampson C, Gill BH, Harrison NK, Nelson A, Byrne A. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med. 2015 Dec 4;15:155.
13. Scelfo C, Caminati A, Harari S. Recent advances in managing idiopathic pulmonary fibrosis. F1000Res. 2017;6:2052.
14. Graney BA, Lee JS. Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Relat Outcome Meas. 2018;9:321–8.
15. van Manen MJG, Geelhoed JJM, Tak NC, Wijsenbeek MS. Optimizing quality of life in patients with idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2017;11(3):157–69.
16. Wuyts WA, Peccatori FA, Russell A-M. Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models. Eur Respir Rev. 2014 Jun;23(132):231–8.
17. Fernández Pérez ER, Zelarney P, Thomas S, Shoop DA, Munson JL, Johnson KD, et al. An educational initiative to improve the team-based care of patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2018 Jan;4(1).
18. Ellis S. The patient-centred care model: holistic/multiprofessional/reflective. Br J Nurs. 1999 Mar 11;8(5):296–301.
19. Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century [Internet]. Washington (DC): National Academies Press (US); 2001 [cited 2019 Jun 25]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK222274/
20. Epner DE, Baile WF. Difficult conversations: teaching medical oncology trainees communication skills one hour at a time. Acad Med. 2014 Apr;89(4):578–84.
21. Shanafelt T, Dyrbye L. Oncologist burnout: causes, consequences, and responses. J Clin Oncol. 2012 Apr 10;30(11):1235–41.
22. Pinto RZ, Ferreira ML, Oliveira VC, Franco MR, Adams R, Maher CG, et al. Patient-centred communication is associated with positive therapeutic alliance: a systematic review. J Physiother. 2012;58(2):77–87.
23. Stewart MA. Effective physician-patient communication and health outcomes: a review. CMAJ. 1995 May 1;152(9):1423–33.
24. Lee SJ, Back AL, Block SD, Stewart SK. Enhancing physician-patient communication. Hematology Am Soc Hematol Educ Program. 2002;464–83.
25. Schapira L. Communication skills training in clinical oncology: the ASCO position reviewed and an optimistic personal perspective. Crit Rev Oncol Hematol. 2003 Apr;46(1):25–31.
26. Lenzi R, Baile WF, Costantini A, Grassi L, Parker PA. Communication training in oncology: results of intensive communication workshops for Italian oncologists. Eur J Cancer Care (Engl). 2011 Mar;20(2):196–203.
27. Moore PM, Rivera S, Bravo-Soto GA, Olivares C, Lawrie TA. Communication skills training for healthcare professionals working with people who have cancer. Cochrane Database Syst Rev. 2018 24;7:CD003751.
28. Barbosa M, Del Piccolo L, Barbosa A. Effectiveness of a brief training program in relational/communication skills for medical residents. Patient Educ Couns. 2019 Jun;102(6):1104–10.
29. Duck A, Spencer LG, Bailey S, Leonard C, Ormes J, Caress A-L. Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs. 2015 May;71(5):1055–65.
30. Maher TM, Molina-Molina M, Russell A-M, Bonella F, Jouneau S, Ripamonti E, et al. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC Pulm Med. 2017 Sep 15;17(1):124.
31. Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, et al. Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration. 2018;96(6):514–24.
32. Russell A-M, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment. BMC Pulm Med. 2016 Jan 14;16:10.
33. Giot C, Maronati M, Schoenheit IB and G. Idiopathic Pulmonary Fibrosis: An EU Patient Perspective Survey [Internet]. Current Respiratory Medicine Reviews. 2013 [cited 2019 Jun 18]. Available from: http://www.eurekaselect.com/114068/article
34. Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. Chron Respir Dis. 2011;8(4):225–31.
35. Masefield S, Cassidy N, Ross D, Powell P, Wells A. Communication difficulties reported by patients diagnosed with idiopathic pulmonary fibrosis and their carers: a European focus group study. ERJ Open Res. 2019 Apr;5(2).
36. Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, et al. Understanding the informational needs of patients with IPF and their caregivers: “You get diagnosed, and you ask this question right away, what does this mean?” BMJ Open Qual. 2018;7(1):e000207.
37. Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, et al. Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers. Chron Respir Dis. 2019 Dec;16:1479973119858961.
38. Suchman AL, Markakis K, Beckman HB, Frankel R. A model of empathic communication in the medical interview. JAMA. 1997 Feb 26;277(8):678–82.
39. Adams WC. Conducting Semi-Structured Interviews. In: Handbook of Practical Program Evaluation [Internet]. John Wiley & Sons, Ltd; 2015 [cited 2019 Sep 9]. p. 492–505. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781119171386.ch19
40. Raimundo K, Kong A, Gray S, Benloucif S, Limb S. Adherence and Persistence to Antifibrotic Treatments for Idiopathic Pulmonary Fibrosis. CHEST [Internet]. 2017 Oct 1 [cited 2019 Jun 19];152(4):A441. Available from: https://journal.chestnet.org/article/S0012-3692(17)31986-4/abstract
41. Corral M, Reddy S, Chang E, Broder M, Gokhale S, Raimundo K. Rates of Adherence and Persistence of Antifibrotic Therapies in the U.S. Medicare Population. In: B103 ILD: THERAPY [Internet]. American Thoracic Society; 2019 [cited 2019 Jun 19]. p. A4094–A4094. (American Thoracic Society International Conference Abstracts). Available from: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4094
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
